Highest-materiality recent filing
CONMED repurchases $645M of 2.25% convertible notes due 2027 for $637M cash
Principle amount of $645.2M at 2.25% coupon due 2027 acquired for $637.2M in cash.
CONMED secures $450M incremental term loan facility to repurchase convertible notes due 2026
Aggregate $450M in incremental delayed draw term A-2 loans available for single draw on or before June 14, 2026.
CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance
Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.
CONMED Q4 sales up 7.9%, adjusted EPS $1.43; FY2026 guidance below 2025 adjusted EPS
Q4 sales $373.2M (+7.9% YoY); GAAP EPS $0.54 vs $1.08, adjusted EPS $1.43 vs $1.34.
CONMED CFO Todd Garner to depart; transition to Special Advisor through Nov 2026
Garner's separation effective by Mar 15, 2026 or upon appointment of new CFO; he will serve as Special Advisor until Nov 2, 2026.
CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026
Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.
CONMED Q3 revenue up 6.7% to $338M; adjusted EPS $1.08; suspends dividend, authorizes $150M buyback
Diluted GAAP EPS $0.09 vs $1.57 YoY due to $19.7M product rationalization and $9.2M consulting costs.
CONMED Q2 adj EPS $1.15 beats; raises FY2025 revenue and adj EPS guidance
Q2 sales $342.3M (+3.1% YoY); GAAP EPS $0.69 (down from $0.96), adj EPS $1.15 (up from $0.98).
CONMED Q1 adjusted EPS $0.95, revenue $321.3M, raises FY2025 guidance
Total sales $321.3M, up 2.9% reported (3.8% constant currency); domestic +4.2%, international +1.2%.
CONMED Q4 2024 sales $345.9M (+5.8% YoY), adjusted EPS $1.34; FY25 guidance issued
Q4 GAAP diluted EPS $1.08 (vs $1.05 YoY); adjusted diluted EPS $1.34 (+26.4%).
CONMED Q3 2024: adj. EPS $1.05 beats; revenue guidance trimmed; CEO transition to Beyer Jan 2025
Sales $316.7M (+4.0% YoY); GAAP EPS $1.57 (vs $0.50); adjusted EPS $1.05 (+16.7%).
CONMED prelim Q3 rev $315-318M; adj EPS growth to exceed 9-11% guide
Revenue expected $315M-$318M for Q3 2024 (preliminary).
CONMED President Bill Peters to depart on August 31, 2024
Employment of Stanley W. (Bill) Peters, President of Advanced Surgical & Advanced Endoscopic Technologies, terminates Aug 31, 2024.
CONMED Q2 adj EPS $0.98 beats; cuts FY revenue & EPS guidance on supply chain delays
Revenue $332.1M (+4.5% reported, +5.2% constant currency); GAAP EPS $0.96 vs $0.43; adj EPS $0.98 vs $0.83 (+18.1%).
GAAP diluted EPS $0.63 vs $0.06 in Q1 2023; adjusted EPS $0.79, up 19.7% YoY.
CONMED Q4 sales $327M (+30.4% YoY); adjusted EPS $1.06 (+152%); guides FY24 rev $1.34-1.365B
Q4 sales $327.0M, +30.4% YoY (31.5% constant currency); domestic +33.3%, intl +26.5% as reported.
CONMED Q3 sales $304.6M (+10.7% YoY); adj. EPS $0.90 (+16.9%); raises FY guidance
Revenue of $304.6M, +10.7% reported (+11.9% constant currency). Domestic +9.5%, International +12.3%.
CONMED Q2 sales +14.6% to $317.7M, adj. EPS $0.83, raises FY guidance
GAAP diluted EPS $0.43 vs loss of $5.65; adjusted diluted EPS $0.83, +9.2% YoY.
CONMED Q1 sales $295.5M (+21.9% YoY); raises FY 2023 revenue and EPS guidance
Sales $295.5M (+21.9% as reported; +25.1% constant currency); acquisitions contributed ~570 bps growth.
CONMED reports Q4 sales down 8.4%, adj. EPS down 60.7% on warehouse software disruption
Q4 sales $250.9M (-8.4% YoY); GAAP EPS $0.86 vs $0.75 YoY; adjusted EPS $0.42 vs $1.07.
CONMED withdraws FY2022 outlook due to warehouse software disruption; provides FY2023 guidance
Service level disruptions from new warehouse software impacted Q4 shipments; backlog peaked at $35M, now $28M.
CONMED Q3 sales $275.1M (+10.6% YoY); adjusted EPS $0.77 misses prior year; narrows 2022 guidance
Sales $275.1M +10.6% as reported, +12.1% constant currency; domestic +14.2%, international +6.2% as reported.
On June 17, 2026, CONMED Corporation (the “Company”) announced that John E. Gallagher has been appointed to serve as the Company’s Executive Vice President, Chief Financial Officer beginning July 15, 2026 (the “Effective Date”).
On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.
On May 19, 2026, the Board appointed Kimberly Lockwood as Interim Corporate Controller and Interim Principal Accounting Officer of the Company effective June 1, 2026.
On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.
On April 1, 2025, Mr. Moller was appointed Principal Accounting Officer
and Todd W. Garner, Executive Vice President of Finance and Chief Financial Officer, ceased serving in the role of Principal Accounting Officer.
Kimberly A. Lockwood, who was acting as Interim Corporate Controller, has been promoted to Senior Director of Financial Reporting.
On February 24, 2025, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Mark Kaye as a director effective immediately.
effective as of October 31, 2024, Curt R. Hartman’s service as Chair of the Board will cease
Commencing on March 3, 2025 (the 'Transition Date'), Mr. Hartman will serve as a Special Advisor
As of the Separation Date, Mr. Hartman’s service relationship with the Company will cease.
Effective as of January 1, 2025, Mr. Hartman will transition into a non-executive officer role
Max materiality 0.85 · Median 0.53 · Most common event earnings